Bupropion alone is an approved smoking-cessation aid, but the fixed-dose combination is not licensed for this purpose. Some clinicians have explored the combo for concurrent weight loss and nicotine-craving reduction, but robust evidence is limited.
Take the tablet with food and stay hydrated. If nausea persists for more than a few days or is accompanied by vomiting, contact a healthcare professional for possible dose adjustment.
Moderate alcohol consumption is generally acceptable, but excessive drinking can increase the risk of seizures associated with bupropion. Limit intake and discuss your alcohol use with your prescriber.
Both ingredients can cause modest increases in blood pressure, especially during dose titration. Regular monitoring is recommended, and dose reduction may be needed if hypertension develops.
No. Concurrent use with a monoamine oxidase inhibitor (or use within 14 days of stopping an MAOI) is contraindicated due to the risk of hypertensive crisis and serotonin syndrome.
Some cold medicines contain decongestants that can raise blood pressure or lower seizure threshold. Consult a pharmacist before combining them with Bupropion + Naltrexone.
Unlike appetite-suppressants that act solely on the central nervous system, this combination targets both reward pathways (via naltrexone) and neurotransmitter reuptake (via bupropion). Efficacy and side-effect profiles vary among agents.
A balanced, calorie-controlled diet enhances weight-loss outcomes, but no specific dietary restrictions are required beyond general healthy-eating guidelines.
If the product is not licensed in the United Kingdom, it may be considered a non-approved medication abroad. Carry a prescription copy, a letter from your doctor, and check the destination country’s regulations before traveling.
Bupropion + Naltrexone is a fixed-dose combination pill that contains two active ingredients: 8 mg of bupropion and 90 mg of naltrexone. The medication is classified within the therapeutic areas of addiction (specifically smoking cessation) and weight management. It is supplied as an oral tablet and, in the United Kingdom, it is not licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for any indication. The combination is approved for chronic weight management in the United States, but it remains unavailable on the UK market.
The onset of action typically begins within a few days for smoking-cessation benefits, while weight-loss effects become noticeable after several weeks of consistent dosing.
Because the medication is not licensed in the UK, any use would be considered off-label and should only occur within a clinical trial or with a specialist’s written justification.
Off-label use must be supervised by a qualified healthcare professional and is not guaranteed to be safe or effective.
Ideal candidates (where licensed)
Absolute contraindications
Relative contraindications / cautions
Patients with renal impairment, active psychiatric conditions, or those taking other medications that lower the seizure threshold should discuss risks with their prescriber.
These effects are usually mild to moderate and often improve with continued therapy.
If any of the following appear, seek urgent medical attention: sudden loss of consciousness, severe chest pain, high fever, persistent vomiting, or signs of an allergic reaction (rash, swelling, difficulty breathing).
Major interactions
MAO inhibitors - increase risk of hypertensive crisis and serotonin syndrome.
Other agents that lower seizure threshold (e.g., antipsychotics, tramadol, certain antibiotics).
Opioid analgesics - naltrexone blocks opioid effects and may precipitate withdrawal.
Moderate interactions
CYP2B6 inhibitors (e.g., clopidogrel, ticlopidine) - may increase bupropion concentrations.
CYP2B6 inducers (e.g., rifampicin, carbamazepine) - may reduce bupropion efficacy.
Antidepressants that increase serotonergic activity (e.g., SSRIs) - monitor for serotonin syndrome when combined with bupropion.
Patients should provide a complete medication list, including over-the-counter drugs and supplements, to their prescriber.
Standard dosing (where licensed):
Start with one tablet (8 mg/90 mg) taken once daily in the morning.
After at least one week, the dose may be increased to two tablets daily (morning and evening) as tolerated.
The maximum recommended dose is three tablets daily (total 24 mg bupropion / 270 mg naltrexone) in the United States. For the UK context, any dosing must be prescribed within a clinical trial or specialist setting.
Administration
Swallow tablets whole with a full glass of water.
Do not crush, chew, or split the tablet.
Take the morning dose with food to minimize nausea; the evening dose may be taken with or without food.
Missed dose
If you miss a dose, take it as soon as you remember provided it is at least 6 hours before the next scheduled dose.
Do not double the dose to make up for a missed tablet.
Overdose
Symptoms may include seizures, rapid heartbeat, high blood pressure, severe nausea, or loss of consciousness.
Seek emergency medical care immediately; treatment is supportive, and activated charcoal may be considered if presentation is early.
Discontinuation
The medication can usually be stopped without tapering, but abrupt cessation may lead to rebound weight gain or return of nicotine cravings. Discuss a cessation plan with your prescriber.
Regular follow-up visits (every 4-6 weeks) enable dose adjustments, safety monitoring, and reinforcement of lifestyle changes.
This article provides educational information about Bupropion + Naltrexone and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
